Feature|Articles|April 1, 2026

FDA updates in urology: March 2026

Fact checked by: Benjamin P. Saylor, Strategic Content Lead

A recap of the FDA submissions and regulatory decisions in urology from March 2026.

Welcome to Urology Times’® monthly FDA update! Regulatory updates in March spanned a broad range of urologic indications, with key approvals across prostate cancer, bladder cancer, and benign prostatic hyperplasia (BPH). A notable trend was the refinement or expansion of existing therapies, underscoring an ongoing commitment to patient-centered care.